scholarly journals CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice

Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2520
Author(s):  
Ritika Kurian ◽  
William Hedrich ◽  
Bryan Mackowiak ◽  
Linhao Li ◽  
Hongbing Wang
Keyword(s):  
Transgenic Mice ◽  
Constitutive Androstane Receptor ◽  
Plasma Concentrations ◽  
Survival Rates ◽  
Pharmacokinetic Profile ◽  
In Vivo Studies ◽  
Chop Regimen ◽  
Transgenic Mouse Line

Non-Hodgkin’s lymphoma (NHL) is a malignant cancer originating in the lymphatic system with a 25–30% mortality rate. CHOP, consisting of cyclophosphamide (CPA), doxorubicin, vincristine, and prednisone, is a first-generation chemotherapy extensively used to treat NHL. However, poor survival rates among patients in advanced stages of NHL shows a need to improve this standard of care treatment. CPA, an integral component of CHOP, is a prodrug that requires CYP2B6-mediated bioactivation to 4-hydroxy-CPA (4-OH-CPA). The expression of CYP2B6 is transcriptionally regulated by the constitutive androstane receptor (CAR, NRi13). We have previously demonstrated that the induction of hepatic CYP2B6 by CITCO, a selective human CAR (hCAR) agonist, results in CHOP’s enhanced antineoplastic effects in vitro. Here, we investigate the in vivo potential of CITCO as an adjuvant of CPA-based NHL treatment in a hCAR-transgenic mouse line. Our results demonstrate that the addition of CITCO to the CHOP regimen leads to significant suppression of the growth of EL-4 xenografts in hCAR-transgenic mice accompanied by reduced expression of cyclin-D1, ki67, Pcna, and increased caspase 3 fragmentation in tumor tissues. CITCO robustly induced the expression of cyp2b10 (murine ortholog of CYP2B6) through hCAR activation and increased plasma concentrations of 4-OH-CPA. Comparing to intraperitoneal injection, oral gavage of CITCO results in optimal hepatic cyp2b10 induction. Our in vivo studies have collectively uncovered CITCO as an effective facilitator for CPA-based NHL treatment with a pharmacokinetic profile favoring oral administration, promoting CITCO as a promising adjuvant candidate for CPA-based regimens.

Design, Synthesis, and Pharmacokinetic Evaluation of O-Carbamoyl Tizoxanide Prodrugs

2020 ◽  
Vol 16 ◽  
Author(s):  
Xi He ◽  
Wenjun Hu ◽  
Fanhua Meng ◽  
Xingzhou Li
Keyword(s):  
Plasma Concentration ◽  
Broad Spectrum ◽  
Plasma Concentrations ◽  
Antiviral Drug ◽  
Systemic Exposure ◽  
Pharmacokinetic Profile ◽  
Hydroxyl Group ◽  
First Pass

Background: The broad-spectrum antiparasitic drug nitazoxanide (N) has been repositioned as a broad-spectrum antiviral drug. Nitazoxanide’s in vivo antiviral activities are mainly attributed to its metabolitetizoxanide, the deacetylation product of nitazoxanide. In reference to the pharmacokinetic profile of nitazoxanide, we proposed the hypotheses that the low plasma concentrations and the low system exposure of tizoxanide after dosing with nitazoxanide result from significant first pass effects in the liver. It was thought that this may be due to the unstable acyloxy bond of nitazoxanide. Objective: Tizoxanide prodrugs, with the more stable formamyl substituent attached to the hydroxyl group rather than the acetyl group of nitazoxanide, were designed with the thought that they might be more stable in plasma. It was anticipated that these prodrugs might be less affected by the first pass effect, which would improve plasma concentrations and system exposure of tizoxanide. Method: These O-carbamoyl tizoxanide prodrugs were synthesized and evaluated in a mouse model for pharmacokinetic (PK) properties and in an in vitro model for plasma stabilities. Results: The results indicated that the plasma concentration and the systemic exposure of tizoxanide (T) after oral administration of O-carbamoyl tizoxanide prodrugs were much greater than that produced by equimolar dosage of nitazoxanide. It was also found that the plasma concentration and the systemic exposure of tizoxanide glucuronide (TG) were much lower than that produced by nitazoxanide. Conclusion: Further analysis showed that the suitable plasma stability of O-carbamoyl tizoxanide prodrugs is the key factor in maximizing the plasma concentration and the systemic exposure of the active ingredient tizoxanide.

Assessing CD97 and CD99 As Markers of Leukaemia Initiating Cells in Paediatric ALL

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1882-1882 ◽  
Author(s):  
Charlotte Victoria Cox ◽  
Paraskevi Diamanti ◽  
Allison Blair
Keyword(s):  
Functional Capacity ◽  
Conflicts Of Interest ◽  
Residual Disease ◽  
Survival Rates ◽  
In Vivo Studies ◽  
Nsg Mice ◽  
Early Treatment Response ◽  
Current Therapies

Abstract Abstract 1882 Overall survival rates in paediatric acute lymphoblastic leukaemia (ALL) have dramatically improved but around 20% do not respond to current therapies and subsequently relapse. Leukaemia initiating cells (LIC) are the topic of much investigation, as these cells can self-renew and may have the potential to cause relapse. It has been shown that multiple subpopulations of ALL cells have the ability to initiate the disease in immune deficient mouse models. Therefore, treatment should be targeted at all cells with this capacity, if the disease is to be eradicated. Minimal residual disease (MRD) detection is an invaluable tracking tool to assess early treatment response and recent studies have highlighted potential markers that may improve the sensitivity of MRD detection by flow cytometry. CD97 and CD99 are two markers which were over expressed in paediatric ALL. Incorporating these markers into investigations of LIC may allow discrimination of leukaemia cells from normal haemopoietic stem cells (HSC). In this study we evaluated the expression of CD34 in combination with CD97 in B cell precursor (BCP) ALL cases and CD99 in T-ALL cases and subsequently assessed the functional capacity of the sorted subpopulations in vitro and in vivo. Ten ALL samples (6 B-ALL & 4 T-ALL) with a median age 7 years (range 2–15 years) were studied. One B-ALL case and 3 T-ALL cases were considered high risk by molecular assessment of MRD at day 28 of treatment. Flow cytometric analyses of the ALL samples and 8 normal haemopoietic cell samples demonstrated that both CD97 and CD99 were over expressed in ALL patients (78.9±14.8% & 76.4±32.8%, respectively) when compared to normal haemopoietic cells (14.1±25.4%; p=0.001, 47.1±10%; p=0.03, respectively). Cells were sorted for expression/lack of expression of these markers and proliferation of the sorted cells was assessed in suspension culture over a 6 week period. In the B-ALL patients the CD34+/CD97+ subpopulation represented the bulk of leukaemia cells (65.2±32.1%), the CD34−/CD97+ the smallest fraction (3.3±2.4%) with the CD34+/CD97− and CD34−/CD97− subpopulations representing 21.1±31.5% and 10.5±5.8% of cells, respectively. When the functional capacity of these subpopulations was assessed in vitro greatest expansion was observed in cells derived from CD34+/CD97− subpopulation (2–173 fold) from 9.4×103 at initiation up to 1.5×106 cells at week 6. Expansion was also observed, to a lesser extent in the CD34−/CD97− subpopulation (3.4–28 fold) from 8×103 up to 1.4×106 cells. No expansion was observed in cultures of CD34+/CD97+ and CD34−/CD97− subpopulations but cells were maintained throughout the culture period. These sorted subpopulations were also inoculated into NOD/LtSz-SCID IL-2Rγc null (NSG) mice to evaluate repopulating capacity. To date, engraftment has been achieved with 3 subpopulations; CD34+/CD97+ (3–28.8% CD45+), CD34+/CD97− (0.5–25.5% CD45+) and CD34−/CD97+ (23.8% CD45+) cells. When the functional capacity of T-ALL cases was assessed the CD34+/CD99+ subpopulation represented the bulk of cells at sorting (51.87±47.2%), the CD34+/CD99- subpopulation was the smallest (0.9±0.8%) and the CD34−/CD99+ and CD34−/CD99− subpopulations represented 32.1±38.9% and 27.2±33.4% of cells, respectively. Greatest expansion was observed in cultures of CD34+/CD99- cells (4.6–1798 fold) from 7.5×103 up to 2.6×106 cells at week 6. The other 3 subpopulations expanded to a lesser extent (1.3–216 fold) from 5×103 up to 1.8×106 cells. When the functional capacity of these cells was assessed in NSG mice, engraftment was achieved in all subpopulations; CD34+/CD99+ (87–90.5% CD45+), CD34+/CD99− (1.5–84.9% CD45+), CD34−/CD99+ (31.3–98.6% CD45+) and CD34−/CD99− (3–92.9% CD45+). In some cases, cells recovered from BM of NSG inoculated with CD99− cells had high expression of CD99, typical of the patient samples at diagnosis, indicating that the inoculated CD99− cells had differentiated in vivo. Studies are ongoing to assess the self-renewal capacity of these subpopulations by serial transplantation. The findings to date indicate that targeting CD97 and CD99, either alone or in combination with CD34 would not eliminate all cells with the capacity to initiate and maintain B-ALL and T-ALL, respectively. Further developments in therapy may require targeting leukaemogenic pathways, rather than only cell surface markers to improve survival outcome in paediatric ALL. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Tudor Petreus ◽  
Elaine Cadogan ◽  
Gareth Hughes ◽  
Aaron Smith ◽  
Venkatesh Pilla Reddy ◽  
...  
Keyword(s):  
Animal Studies ◽  
Drug Exposure ◽  
Drug Effects ◽  
Pharmacokinetic Profile ◽  
Microfluidic System ◽  
Drug Dose ◽  
In Vivo Studies ◽  
On Chip

AbstractMicrophysiological in vitro systems are platforms for preclinical evaluation of drug effects and significant advances have been made in recent years. However, existing microfluidic devices are not yet able to deliver compounds to cell models in a way that reproduces the real physiological drug exposure. Here, we introduce a novel tumour-on-chip microfluidic system that mimics the pharmacokinetic profile of compounds on 3D tumour spheroids to evaluate their response to the treatments. We used this platform to test the response of SW620 colorectal cancer spheroids to irinotecan (SN38) alone and in combination with the ATM inhibitor AZD0156, using concentrations mimicking mouse plasma exposure profiles of both agents. We explored spheroid volume and viability as a measure of cancer cells response and changes in mechanistically relevant pharmacodynamic biomarkers (γH2AX, cleaved-caspase 3 and Ki67). We demonstrate here that our microfluidic tumour-on-chip platform can successfully predict the efficacy from in vivo studies and therefore represents an innovative tool to guide drug dose and schedules for optimal efficacy and pharmacodynamic assessment, while reducing the need for animal studies.

Qualitative and Quantitative Analysis of Resveratrol and Oxyresveratrol by Liquid Chromatography

2020 ◽  
Vol 7 (1) ◽  
pp. 24-31
Author(s):  
Rajeshree Khambadkar ◽  
Selvan Ravindran ◽  
Digamber Singh Chahar ◽  
Srushti Utekar ◽  
Amlesh Tambe
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
High Performance ◽  
Pharmacokinetic Profile ◽  
Quantitative Information ◽  
In Vivo Studies ◽  
Chromatography Method ◽  
Qualitative And Quantitative

Introduction: Resveratrol and its monooxygenated metabolite oxyresveratrol were the subject matter of intense research due to their medicinal value. Absorption, distribution, metabolism and excretion are important to understand the bioavailability and pharmacokinetic profile of resveratrol and oxyresveratrol. Quantification of resveratrol and oxyresveratrol is essential for both in vitro and in vivo studies. Methods: During in vitro drug metabolism studies, both qualitative and quantitative information are essential to understand the metabolic profile of resveratrol and oxyresveratrol. In the present study, a simple and stable method is outlined using high performance liquid chromatography to quantify both resveratrol and oxyresveratrol. This method is suitable to understand the metabolic stability, plasma stability, pharmacokinetics and toxicokinetics of resveratrol and oxyresveratrol. Results: Generally, in vitro incubation studies are performed at high concentrations and in vivo studies are carried out at both high and low concentrations, therefore high performance liquid chromatography method is demonstrated as a suitable technique to quantify resveratrol and oxyresveratrol. Conclusion: Retention time of resveratrol and oxyresveratrol from liquid chromatography qualitatively confirm its identity.

scholarly journals In Vitro and In Vivo Activities of Syn2836, Syn2869, Syn2903, and Syn2921: New Series of Triazole Antifungal Agents

2001 ◽  
Vol 45 (9) ◽  
pp. 2420-2426 ◽  
Author(s):  
S. M. Salama ◽  
H. Atwal ◽  
A. Gandhi ◽  
J. Simon ◽  
M. Poglod ◽  
...  
Keyword(s):  
Antifungal Agents ◽  
Survival Rates ◽  
Systemic Infection ◽  
Kinetic Studies ◽  
The Other ◽  
In Vivo Studies ◽  
Infection Model ◽  
Time Kill

ABSTRACT The in vitro and in vivo activities of four azole compounds belonging to a new series of 2(2,4-difluorophenyl)-3-(4-substituted piperazin-1-yl)-1-(1,2,4-triazol-1-yl) butanol antifungal agents is described. The compounds were selected from a library of azole compounds synthesized by our group. The in vitro activities of Syn2869, Syn2836, Syn2903, and Syn2921 against a panel of over 240 recently collected clinical isolates of yeast and molds were determined, and the results were compared with those obtained with fluconazole (FLC), itraconazole (ITC), and amphotericin B (AMB). The MICs at which 90% of the isolates were inhibited (MIC90s) for the four test compounds for strains of Candida spp. ranged from <0.048 to 0.78 μg/ml. All compounds were also active against FLC-resistant Candida albicans and otherCandida sp. strains. Moreover, MIC90s for strains of Cryptococcus neoformans,Aspergillus spp., Trichophyton spp., andMicrosporum spp. were also low and ranged from <0.048 to 0.39 μg/ml. The test compounds produced a fungistatic pattern during the time-kill kinetic studies. In vivo studies indicated that all four test compounds have good efficacies against C. albicans in a murine systemic infection model and significantly improved the survival rates of the infected mice. The results for Syn2903 were similar to those for FLC, while the other compounds were slightly less effective but had ranges of activities similar to the range of activity of ITC. The compounds were also evaluated against anAspergillus fumigatus systemic infection. Syn2903 was also superior to ITC, whereas the efficacy data for the other compounds were similar to those for ITC. It was concluded from the data generated for this new series of azole compounds in the studies described above that further pharmacokinetic and toxicologic evaluations are warranted prior to selection of a candidate compound for preclinical testing.

M945. Nonhepahinic Mucopolisacarid. In Vivo Studies(Humans)

1979 ◽  
Author(s):  
K. Giuliani ◽  
E. Stwarcer
Keyword(s):  
Plasma Concentrations ◽  
In Vitro Studies ◽  
In Vivo Studies ◽  
Healthy Individuals ◽  
Enhanced Activity ◽  
Post Infusion ◽  
Level 1 ◽  
Made In

It has been reported,in in vivo studies (doga, rabbita), that the antithrombotic protection of heparin is clearly related to AntiXa enhanced activity,than to a particular KCCT level(1)(2)In this work, 20 healthy individuals were studied. KCCT, TT, AntiXa (Denaon-Bonnar) deter minations were made. In vitro studies of M945 actiona on these tests, at different plasma concentrations of the drug (0.02-0.2UI/al) were performed.M945 waa then SC administered, 100UI/kg weight, and blood aamples collected each two houra, and KCCT, TT, AntiXa studied.In vitro samples showed no differences in KCCT, TT, and Anti Xa activity, that the ones expected when using heparin. In 16 humana, in post infusion studie s, it was seen that nearly no changea on KCCT or TT occured,vhile AntiAa waS enhanced in its activity, up to 90" (more than corresponding valuea for 0.2UI/al of heparin in plaamal.Further work with similar drugs to M945, should open the poasibility of safe antithrombotic treatments in patients with anticoagulant contraindications.1. Szwarcer E, Giuliani R, vIII World Congr Cardiol, Abatr, 1, 1159, pg 381, 19782. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent H, Elood, Vol 49, N82, 171, (feb), 1977

scholarly journals Tritium labeling of antisense oligonucleotides via different conjugation agents

AAPS Open ◽  
2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Martin R. Edelmann ◽  
Christophe Husser ◽  
Martina B. Duschmalé ◽  
Guy Fischer ◽  
Claudia Senn ◽  
...  
Keyword(s):  
Antisense Oligonucleotides ◽  
Specific Activity ◽  
Plasma Concentrations ◽  
In Vivo Studies ◽  
Radioactive Label ◽  
Target Interaction ◽  
Time Profiles ◽  
Novel Approach

AbstractA novel approach to tritium-labeled antisense oligonucleotides (ASO) was established by conjugating N-succinimidyl propionate, as well as maleimide-derivatives, to the 3′-end of ASOs targeting metastasis-associated lung adenocarcinoma transcript 1 (Malat1) containing amino- or sulfhydryl-linkers. In vitro stability and Malat1 RNA reduction studies demonstrated that N-ethylmaleimide (NEM) could be used as a stable tag while maintaining the desired target interaction. The corresponding radioactive label conjugation using [3H]-NEM resulted in tritium-labeled ASOs with a high molar specific activity of up to 17 Ci/mmol. Single-dose in vivo studies in mice were carried out to compare [3H]-ASOs with their unlabeled counterpart ASOs, with and without conjugation to N-acetylgalactosamine (GalNAc), for tissue and plasma concentrations time profiles. Despite the structural modification of the labeled ASOs, in vitro target interaction and in vivo pharmacokinetic behaviors were similar to that of the unlabeled ASOs. In conclusion, this new method provides a powerful technique for fast and safe access to tritium-labeled oligonucleotides, e.g., for pharmacokinetic, mass balance, or autoradiography studies. Graphical abstract

GENERATION OF TRANSGENIC MICE FOR IN VIVO DETECTION OF INSULIN-CONTAINING GRANULE EXOCYTOSIS AND QUANTIFICATION OF INSULIN SECRETION

2009 ◽  
Vol 02 (04) ◽  
pp. 397-405 ◽  
Author(s):  
JINLING LU ◽  
NATALIA GUSTAVSSON ◽  
QIMING LI ◽  
GEORGE K. RADDA ◽  
THOMAS C. SÜDHOF ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Transgenic Mice ◽  
Fluorescent Proteins ◽  
Secretory Granules ◽  
Cellular Mechanisms ◽  
Transgenic Mouse Line ◽  
Molecular Events ◽  
Insulin Secretion In Vitro

Insulin secretion is a complex and highly regulated process. Although much progress has been made in understanding the cellular mechanisms of insulin secretion and regulation, it remains unclear how conclusions from these studies apply to living animals. That few studies have been done to address these issues is largely due to the lack of suitable tools in detecting secretory events at high spatial and temporal resolution in vivo. When combined with genetically encoded biosensor, optical imaging is a powerful tool for visualization of molecular events in vivo. In this study, we generated a DNA construct encoding a secretory granule resident protein that is linked with two spectrally separate fluorescent proteins, a highly pH-sensitive green pHluorin on the intra-granular side and a red mCherry in the cytosol. Upon exocytosis of secretory granules, the dim pHluorin inside the acidic secretory granules became highly fluorescent outside the cells at neutral pH, while mCherry fluorescence remained constant in the process, thus allowing ratiometric quantification of insulin secretory events. Furthermore, mCherry fluorescence enabled tracking the movement of secretory granules in living cells. We validated this approach in insulin-secreting cells, and generated a transgenic mouse line expressing the optical sensor specifically in pancreatic β-cells. The transgenic mice will be a useful tool for future investigations of molecular mechanism of insulin secretion in vitro and in vivo.

scholarly journals DDIS-21. IN VITRO MICRODIALYSIS RECOVERY OF TRAMETINIB

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi67-vi67
Author(s):  
Carlos Romo ◽  
Nicole Anders ◽  
Morgan Scardina ◽  
Debraj Mukherjee ◽  
Stuart Grossman ◽  
...  
Keyword(s):  
Aqueous Solubility ◽  
Pharmacokinetic Profile ◽  
Primary Objective ◽  
Mitogen Activated Protein Kinase ◽  
In Vivo Studies ◽  
Limit Of Quantification ◽  
Relative Recovery ◽  
Two Samples

Abstract BACKGROUND Dysregulation of the mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K) pathways is common in several primary brain tumors and metastatic cancers affecting the central nervous system. Trametinib, and oral MEK1/2 inhibitor, has been effective in preclinical studies against a variety of cell lines and improves survival in select patients with gliomas. Unfortunately, limited and often short-lived benefits are frequently seen in patients. A potential explanation for this is insufficient blood brain barrier penetration at therapeutic concentrations. The primary objective of this study is to measure the in vitro relative recovery of trametinib using microdialysis to establish the feasibility of characterizing its intratumoral pharmacokinetics in vivo using this technique. METHODS In vitro recovery experiments were performed utilizing commercially available microdialysis instruments. Two perfusion rates (0.5–1µL/min), the use of iso- and hypertonic perfusates (artificial CSF and 10% bovine serum albumin in PBS), and the addition of dimethyl sulfoxide (DMSO) were evaluated using the extraction efficiency method. Liquid chromatography-tandem mass spectrometry was used to measure the concentrations of trametinib in stock solutions, dialysate samples, and controls over time. RESULTS Dialysate was initially collected from a solution spiked with 15ng/mL at a rate of 1µL/min for 60 minutes, the recovery was 0.3ng/mL (0.2%) in two samples and below the limit of quantification (< 0.2ng/mL) in three. Dialysate samples were then collected from a stock solution with 150ng/mL of trametinib, recovery ranged from 0.3–15.3ng/mL (0.2–10.2%) in nine detectable samples out of sixteen. Recovery was greater with the addition of DMSO to the perfusate and with the use of a hypertonic perfusate. CONCLUSIONS The poor relative recovery of trametinib using microdialysis suggests that this technique would be unreliable in in vivo studies. Trametinib has poor aqueous solubility, limiting the ability of characterizing its pharmacokinetic profile through microdialysis.

Sign in / Sign up

Export Citation Format

Share Document